全文获取类型
收费全文 | 7504篇 |
免费 | 456篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 113篇 |
妇产科学 | 129篇 |
基础医学 | 820篇 |
口腔科学 | 102篇 |
临床医学 | 913篇 |
内科学 | 1376篇 |
皮肤病学 | 83篇 |
神经病学 | 670篇 |
特种医学 | 441篇 |
外国民族医学 | 1篇 |
外科学 | 848篇 |
综合类 | 74篇 |
一般理论 | 8篇 |
预防医学 | 1036篇 |
眼科学 | 91篇 |
药学 | 530篇 |
中国医学 | 4篇 |
肿瘤学 | 674篇 |
出版年
2024年 | 4篇 |
2023年 | 32篇 |
2022年 | 71篇 |
2021年 | 143篇 |
2020年 | 77篇 |
2019年 | 149篇 |
2018年 | 193篇 |
2017年 | 129篇 |
2016年 | 135篇 |
2015年 | 180篇 |
2014年 | 229篇 |
2013年 | 466篇 |
2012年 | 601篇 |
2011年 | 630篇 |
2010年 | 354篇 |
2009年 | 343篇 |
2008年 | 549篇 |
2007年 | 537篇 |
2006年 | 507篇 |
2005年 | 493篇 |
2004年 | 515篇 |
2003年 | 544篇 |
2002年 | 455篇 |
2001年 | 63篇 |
2000年 | 40篇 |
1999年 | 76篇 |
1998年 | 83篇 |
1997年 | 53篇 |
1996年 | 45篇 |
1995年 | 42篇 |
1994年 | 32篇 |
1993年 | 33篇 |
1992年 | 22篇 |
1991年 | 26篇 |
1990年 | 9篇 |
1989年 | 6篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 4篇 |
1985年 | 10篇 |
1984年 | 14篇 |
1983年 | 9篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1974年 | 3篇 |
1930年 | 2篇 |
1926年 | 2篇 |
排序方式: 共有7968条查询结果,搜索用时 0 毫秒
101.
102.
Cristina Menni Eric Fauman Idil Erte John R.B. Perry Gabi Kastenmüller So-Youn Shin Ann-Kristin Petersen Craig Hyde Maria Psatha Kirsten J. Ward Wei Yuan Mike Milburn Colin N.A. Palmer Timothy M. Frayling Jeff Trimmer Jordana T. Bell Christian Gieger Rob P. Mohney Mary Julia Brosnan Karsten Suhre Nicole Soranzo Tim D. Spector 《Diabetes》2013,62(12):4270-4276
Using a nontargeted metabolomics approach of 447 fasting plasma metabolites, we searched for novel molecular markers that arise before and after hyperglycemia in a large population-based cohort of 2,204 females (115 type 2 diabetic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjects) from TwinsUK. Forty-two metabolites from three major fuel sources (carbohydrates, lipids, and proteins) were found to significantly correlate with T2D after adjusting for multiple testing; of these, 22 were previously reported as associated with T2D or insulin resistance. Fourteen metabolites were found to be associated with IFG. Among the metabolites identified, the branched-chain keto-acid metabolite 3-methyl-2-oxovalerate was the strongest predictive biomarker for IFG after glucose (odds ratio [OR] 1.65 [95% CI 1.39–1.95], P = 8.46 × 10−9) and was moderately heritable (h2 = 0.20). The association was replicated in an independent population (n = 720, OR 1.68 [ 1.34–2.11], P = 6.52 × 10−6) and validated in 189 twins with urine metabolomics taken at the same time as plasma (OR 1.87 [1.27–2.75], P = 1 × 10−3). Results confirm an important role for catabolism of branched-chain amino acids in T2D and IFG. In conclusion, this T2D-IFG biomarker study has surveyed the broadest panel of nontargeted metabolites to date, revealing both novel and known associated metabolites and providing potential novel targets for clinical prediction and a deeper understanding of causal mechanisms.Currently, stratification of individuals at risk for type 2 diabetes (T2D) within the general population is based on well-established factors such as age, BMI, and fasting glucose (1). Although these factors contribute considerably to disease risk, they may not identify at-risk individuals before the disease process is well under way.Recently, a number of studies have found several metabolites to be correlated with insulin resistance and T2D (2–6), and T2D-associated metabolic profiles have been identified 10–15 years before the diagnosis/onset of the disease (7–9). To help preventive strategies, and maximize the potential for existing effective interventions, it is important to characterize the molecular changes that take place in the development of T2D.We aim to understand other biochemical changes, in addition to hyperglycemia, that take place at the onset of T2D using the largest metabolomic screening approach to date. We assessed >400 metabolites to determine which metabolomic profiles are correlated with T2D and impaired fasting glucose (IFG) in a large cohort of females from TwinsUK with independent replication. 相似文献
103.
104.
Healey JS Merchant R Simpson C Tang T Beardsall M Tung S Fraser JA Long L van Vlymen JM Manninen P Ralley F Venkatraghavan L Yee R Prasloski B Sanatani S Philippon F;Canadian Cardiovascular Society;Canadian Anesthesiologists' Society;Canadian Heart Rhythm Society 《The Canadian journal of cardiology》2012,28(2):141-151
There are more than 200,000 Canadians living with permanent pacemakers or implantable defibrillators, many of whom will require surgery or invasive procedures each year. They face potential hazards when undergoing surgery; however, with appropriate planning and education of operating room personnel, adverse device-related outcomes should be rare. This joint position statement from the Canadian Cardiovascular Society (CCS) and the Canadian Anesthesiologists' Society (CAS) has been developed as an accessible reference for physicians and surgeons, providing an overview of the key issues for the preoperative, intraoperative, and postoperative care of these patients. The document summarizes the limited published literature in this field, but for most issues, relies heavily on the experience of the cardiologists and anesthesiologists who contributed to this work. This position statement outlines how to obtain information about an individual's type of pacemaker or implantable defibrillator and its programming. It also stresses the importance of determining if a patient is highly pacemaker-dependent and proposes a simple approach for nonelective evaluation of dependency. Although the document provides a comprehensive list of the intraoperative issues facing these patients, there is a focus on electromagnetic interference resulting from electrocautery and practical guidance is given regarding the characteristics of surgery, electrocautery, pacemakers, and defibrillators which are most likely to lead to interference. The document stresses the importance of preoperative consultation and planning to minimize complications. It reviews the relative merits of intraoperative magnet use vs reprogramming of devices and gives examples of situations where one or the other approach is preferable. 相似文献
105.
106.
107.
Schapira MM Fletcher KE Hayes A Eastwood D Patterson L Ertl K Whittle J 《Journal of clinical hypertension (Greenwich, Conn.)》2012,14(7):461-466
Hypertension knowledge is an integral component of the chronic care model. A valid scale to assess hypertension knowledge and self-management skills is needed. The hypertension evaluation of lifestyle and management (HELM) scale was developed as part of a community-based study designed to improve self-management of hypertension. Participants included 404 veterans with hypertension. Literature review and an expert panel were used to identify required skills. Items were generated and pilot tested in the target population. Validity was assessed through comparisons of performance with education, health numeracy, print numeracy, patient activation and self-efficacy, and hypertension control. The HELM knowledge scale had 14 items across 3 domains: general hypertension knowledge, lifestyle and medication management, and measurement and treatment goals. Scores were positively associated with education (0.28, P<.0001), print health literacy (0.21, P<.001), health numeracy (0.17, P<.001), and patient activation (0.12, P=.015) but no association was found with diastolic or systolic blood pressure. The HELM knowledge scores increased following the educational intervention from baseline (mean, 8.7; standard deviation, 2.2) to 12-month follow-up (mean, 9.2, standard deviation, 2.2; P<.001). We conclude that the HELM provides a valid measure of the knowledge required for patients to take an active role in the chronic disease management of hypertension. 相似文献
108.
109.
Bijan Ghassemieh Vivek N. Ahya Maher A. Baz Vincent G. Valentine Selim M. Arcasoy Robert B. Love Harish Seethamraju Charles G. Alex Remzi Bag Nilto C. DeOliveira Wickii T. Vigneswaran Jeff Charbeneau Edward R. Garrity Sangeeta M. Bhorade 《The Journal of heart and lung transplantation》2013,32(7):701-706
110.
Scott Worley MD BScPT Jeff Pike MD David Anderson MD Jo-Anne Douglas BSc Kara Thompson BSc MSc 《The journal of spinal cord medicine》2013,36(4):379-387
Background: When venous thromboembolism (VTE) includes deep-vein thrombosis (DVT) and pulmonary embolism (PE), patients with acute traumatic spinal cord injury (SCI) have the highest incidence of VTE among all hospitalized groups, with PE the third most common cause of death. Although low-molecular-weight heparin (LMWH) outperforms low-dose unfractionated heparin (LDUH) in other patient populations, the evidence in SCI remains less robust.Objective: To determine whether the efficacy for LMWH shown in previous SCI surveillance studies (eg, routine Doppler ultrasound) would translate into real-world effectiveness in which only clinically evident VTE is investigated (ie, after symptoms or signs present).Methods: A retrospective cohort study was conducted of 90 patients receiving LMWH dalteparin (5,000 U daily) or LDUH (5,000 U twice daily) for VTE prophylaxis after acute traumatic SCI. The incidence of radiographically confirmed VTE was primarily analyzed, and secondary outcomes included complications of bleeding and heparin-induced thrombocytopenia.Results: There was no statistically significant association (p = 0.7054) between the incidence of VTE (7.78% overall) and the type of prophylaxis received (LDUH 3/47 vs dalteparin 4/43). There was no significant differences in complications, location of VTE, and incidence of fatal PE. Paraplegia (as opposed to tetraplegia) was the only risk factor identified for VTE.Conclusions: There continues to be an absence of definitive evidence for dalteparin (or other LMWH) over LDUH as the choice for VTE prophylaxis in patients with SCI. Novel approaches to VTE prophylaxis are urgently required for this population, whose risk of fatal PE has not decreased over the last 25 years. 相似文献